Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 3 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Qui est le CEO de Matinas BioPharma Holdings Inc ?
Mr. Jerome Jabbour est le Chairman of the Board de Matinas BioPharma Holdings Inc, il a rejoint l'entreprise depuis 2013.
Quelle est la performance du prix de l'action MTNB ?
Le prix actuel de MTNB est de $0.52, il a diminué de 4.84% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Matinas BioPharma Holdings Inc ?
Matinas BioPharma Holdings Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Matinas BioPharma Holdings Inc ?
La capitalisation boursière actuelle de Matinas BioPharma Holdings Inc est de $3.3M
Est-ce que Matinas BioPharma Holdings Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Matinas BioPharma Holdings Inc, y compris 0 achat fort, 0 achat, 4 maintien, 1 vente et 0 vente forte